Foghorn Therapeutics (FHTX) Return on Sales (2020 - 2026)

Foghorn Therapeutics' Return on Sales history runs 7 years deep, the most recent figure standing at 0.06% for Q1 2026.

• In Q1 2026, Return on Sales fell 3.0% year-over-year to 0.06%; the TTM figure through Mar 2026 stood at 0.03% (up 1.0% YoY), while the FY2025 annual figure was 0.03%, up 1.0% from the prior year.
• Return on Sales was 0.06% for Q1 2026 at Foghorn Therapeutics, down from 0.02% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q3 2023 to a low of 0.07% in Q4 2022.
• Historically, Return on Sales has averaged 0.04% across 5 years, with a median of 0.04% in 2023.
• The sharpest annual moves came in 2022 and 2024: Return on Sales surged 649 bps in 2022, then fell 3 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 0.07% in 2022, then soared by 39 bps to 0.04% in 2023, then slumped by 63 bps to 0.07% in 2024, then surged by 65 bps to 0.02% in 2025, then slumped by 153 bps to 0.06% in 2026.
• The last three Return on Sales figures came in at 0.06% (Q1 2026), 0.02% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.